• Explore /
  • Poster
  • / Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

Abstract Video & Slides Poster

Authors

Lorenzo Falchi

Lorenzo Falchi

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

Lorenzo Falchi , Carmelo Carlo-Stella , Franck Morschhauser , Martin Hutchings , Emmanuel Bachy , Guillaume Cartron , Cyrus Khan , Monica Tani , Joaquin Martinez-Lopez , Nancy L. Bartlett , Antonio Salar , Joshua Brody , Sirpa Leppä , Estafania Mulvihill , Linda Lundberg , James Relf , Yuying Xie , Alessia Bottos , Kathryn Humphrey , Michael Dickinson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03075696

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7550)

DOI

10.1200/JCO.2023.41.16_suppl.7550

Abstract #

7550

Poster Bd #

101

Abstract Disclosures

Similar Posters

First Author: Pier Luigi Zinzani

First Author: Charles Herbaux

First Author: B. Pro

First Author: Stéphane De Botton